US2011059949A1PendingUtilityA1

Prophylaxis and treatment of infectious diseases

38
Assignee: GULBINS ERICHPriority: Aug 23, 2002Filed: Sep 15, 2010Published: Mar 10, 2011
Est. expiryAug 23, 2022(expired)· nominal 20-yr term from priority
Inventors:Erich Gulbins
A61P 33/06A61P 31/12A61P 31/18A61P 31/16A61P 33/00A61P 31/04A61P 31/14A61P 31/00A61P 11/00A61K 31/137A61K 31/55Y02A50/30
38
PatentIndex Score
0
Cited by
0
References
0
Claims

Abstract

The invention relates to the use of inhibitors of acid sphingomyelinase and/or of inhibitors of products of the reaction catalyzed by this enzyme, for the prophylaxis and/or treatment of infectious diseases and/or diseases which are influenced by infections during the course thereof. The cited products especially include ceramide. Preferrably neutralizing antibodies and/or antidepressants, especially tricyclic and/or tetracyclic antidepressants, are used as inhibitors.

Claims

exact text as granted — not AI-modified
1 .- 18 . (canceled) 
     
     
         19 . A method of treating an infection, comprising:
 administering to a patient by inhalation, a formulation comprising a carrier and an antidepressant selected from the group consisting of a tricyclic antidepressant, and a tetracyclic antidepressant.   
     
     
         20 . The method of  claim 19 , wherein the antidepressant is a tricyclic antidepressant. 
     
     
         21 . The method of  claim 19 , wherein the antidepressant is a tetracyclic antidepressant. 
     
     
         22 . The method of  claim 19 , wherein the antidepressant is selected from the group consisting of amitryptiline and imipramine. 
     
     
         23 . The method of  claim 19 , wherein the formulation comprises amitryptiline. 
     
     
         24 . The method of  claim 19 , wherein the formulation comprises imipramine. 
     
     
         25 . The method of  claim 19 , wherein the infection is an HIV infection. 
     
     
         26 . A method of treating cystic fibrosis, comprising:
 administering to a cystic fibrosis patient by inhalation, a formulation comprising an antidepressant selected from the group consisting of a tricyclic antidepressant, and a tetracyclic antidepressant.   
     
     
         27 . The method of  claim 26 , wherein the antidepressant is a tricyclic antidepressant. 
     
     
         28 . The method of  claim 26 , wherein the antidepressant is a tetracyclic antidepressant. 
     
     
         29 . The method of  claim 26 , wherein the antidepressant is selected from the group consisting of amitryptiline and imipramine. 
     
     
         30 . The method of  claim 26 , wherein the formulation comprises amitryptiline. 
     
     
         31 . The method of  claim 26 , wherein the formulation comprises imipramine. 
     
     
         32 . A method of treating an infection, comprising:
 administering to a patient by inhalation, a formulation consisting essentially of a carrier and an antidepressant selected from the group consisting of a tricyclic antidepressant, and a tetracyclic antidepressant.   
     
     
         33 . The method of  claim 32 , wherein the antidepressant is a tricyclic antidepressant. 
     
     
         34 . The method of  claim 32 , wherein the antidepressant is a tetracyclic antidepressant. 
     
     
         35 . The method of  claim 32 , wherein the antidepressant is selected from the group consisting of amitryptiline and imipramine. 
     
     
         36 . The method of  claim 32 , wherein the antidepressant is amitryptiline. 
     
     
         37 . The method of  claim 32 , wherein the antidepressant is imipramine. 
     
     
         38 . The method of  claim 32 , wherein the infection is an HIV infection.

Join the waitlist — get patent alerts

Track US2011059949A1 — get alerts on status changes and closely related new filings.

We store only your email — no account needed. See our privacy policy.